Equity Overview
Price & Market Data
Price: $6.28
Daily Change: -$0.11 / 1.75%
Daily Range: $6.14 - $6.69
Market Cap: $1,097,409,152
Daily Volume: 1,358,911
Performance Metrics
1 Week: -2.68%
1 Month: 4.58%
3 Months: 25.15%
6 Months: 121.9%
1 Year: 100.3%
YTD: 14.90%
Company Details
Employees: 35
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; and CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies. It also develops CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A; and VEGF-IO Bispecific / Multiple, a bispecific antibody for angiogenesis pathway and anti-tumor immune that targets, including immune checkpoints, as well as analyzes VEGF combinations with other immune response-related proteins. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.